SOTAC

Sotac Pharmaceuticals financials

Market cap
₹100 Cr
Sector
Healthcare

Quarterly results

Q4 FY26: revenue up 15.4%, net profit up 0.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY23Q4 FY23Q2 FY24Q4 FY24Q2 FY25Q4 FY25Q2 FY26Q4 FY26
Revenue40 38 52 52 53 +33%47 +24%37 −29%60 +15%
EBITDA3 4 4 4 4 +33%12 +200%4 +0%10 +150%
Net profit2 1 2 3 2 +0%6 +500%2 +0%3 +0%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −28.8% 1Y

₹100₹120₹140Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Aug 26

1Y: ₹126.4 on 10 Sept 2025 → ₹90.05. High ₹139.65 (2 Dec 2025), low ₹87.4 (13 Aug 2026).

Balance sheet

Year endingFY20FY21FY23FY24FY25FY26
Equity capital₹2 Cr₹2 Cr₹8 Cr₹11 Cr₹11 Cr₹11 Cr
Reserves₹1 Cr₹0 Cr₹11 Cr₹34 Cr₹45 Cr₹48 Cr
Borrowings₹13 Cr₹17 Cr₹22 Cr₹25 Cr₹38 Cr₹38 Cr
Other liabilities₹14 Cr₹15 Cr₹32 Cr₹35 Cr₹29 Cr₹37 Cr
Total liabilities₹30 Cr₹35 Cr₹74 Cr₹105 Cr₹123 Cr₹133 Cr
Fixed assets₹16 Cr₹17 Cr₹26 Cr₹36 Cr₹47 Cr₹50 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹5 Cr₹1 Cr₹2 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹2 Cr₹3 Cr₹3 Cr
Other assets₹14 Cr₹18 Cr₹48 Cr₹63 Cr₹72 Cr₹79 Cr
Total assets₹30 Cr₹35 Cr₹74 Cr₹105 Cr₹123 Cr₹133 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Mar 2026

Since Mar 2025, FIIs added +1.67 pp while the public trimmed −0.99 pp. The shareholder count shrank 9% to 221.

Promoters
72.8%
FIIs
16.8%
Public
10.4%

Since Mar 2025

  • FIIs +1.67 pp
  • Public −0.99 pp
  • DIIs −0.68 pp

How it drifted, 7 quarters

Over this window FIIs went from 12.9% to 16.8% — +3.9 pp.

Apr '23Sep '24Mar '26

Ownership split by quarter, oldest first. Apr '23: Promoters 72.8%, FIIs 12.9%, Public 14.3%.Sep '23: Promoters 72.8%, FIIs 8.5%, Public 18.6%.Mar '24: Promoters 72.8%, FIIs 9.0%, Public 18.2%.Sep '24: Promoters 72.8%, FIIs 8.9%, Public 18.3%.Mar '25: Promoters 72.8%, FIIs 15.1%, DIIs 0.7%, Public 11.3%.Sep '25: Promoters 72.8%, FIIs 16.1%, Public 11.0%.Mar '26: Promoters 72.8%, FIIs 16.8%, Public 10.4%.

Who was buying across the market this quarter →

Who bought this quarter

since Sep 2025

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Mar 2026 filing

Every holder of Sotac Pharmaceuticals Ltd above SEBI's 1% disclosure line, and what changed since Sep 2025.

HolderStakeChange
Kiran Baldevbhai Jotania 13.11%unchanged
Vishalkumar Devrajbhai Patel 12.95%unchanged
Sharadkumar Dashrathbhai Patel 12.95%unchanged
Dineshkumar Babulal Gelot 12.95%unchanged
Chetankumar Bachubhai Patel 9.68%unchanged
NAV Capital Vcc - NAV Capital Emerging Star Fund FPI fund7.35%+0.26 pp
Shaileshkumar Vishnuprasad Patel 7.29%unchanged
Craft Emerging Market Fund Pcc- Elite Capital Fund FPI fund7.12%+0.17 pp
Mitul Shaileshkumar Patel 3.28%unchanged
Minerva Ventures Fund FPI fund1.64%unchanged
Kashyapkumar Rajendrakumar Mehta . 1.54%newly disclosed
Walpar Nutritions Limited 1.49%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Sotac Pharmaceuticals Ltd

Guides on how to read this kind of business and the numbers that matter.